These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 2901136)

  • 21. [Effects on growth hormone secretion of a new somatostatin analogue (SMS 201-995) and nonspecific releasing hormones in patients with acromegaly].
    Candrina R
    Medicina (Firenze); 1988; 8(2):180-1. PubMed ID: 3147351
    [No Abstract]   [Full Text] [Related]  

  • 22. Somatostatin octapeptide (SMS 201-995) in the medical treatment of acromegaly.
    Wass JA; Lytras N; Besser GM
    Scand J Gastroenterol Suppl; 1986; 119():136-40. PubMed ID: 2876497
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Studies on the response of growth hormone (GH) secretion to GH-releasing hormone, thyrotropin-releasing hormone, gonadotropin-releasing hormone, and somatostatin in acromegaly.
    Shibasaki T; Hotta M; Masuda A; Imaki T; Obara N; Hizuka N; Takano K; Wakabayashi I; Demura H; Ling N
    J Clin Endocrinol Metab; 1986 Jul; 63(1):167-73. PubMed ID: 2872226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Current therapeutic possibilities with growth hormone releasing hormone and somatostatin].
    Lamberts SW
    Ned Tijdschr Geneeskd; 1986 May; 130(20):904-8. PubMed ID: 2873514
    [No Abstract]   [Full Text] [Related]  

  • 25. [Preoperative administration of a slow releasing somatostatin analog (SR-lanreotide, BIM 23014) in patients with acromegaly in the course of GH-releasing adenoma].
    Zieliński G; Podgórski JK; Koziarski A; Siwik J; Zgliczyński W; Wieliczko W
    Neurol Neurochir Pol; 2001; 35(3):423-37. PubMed ID: 11732266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inadequate growth hormone (GH) suppression following an octreotide test dose predicts the need for adjuvant therapy to achieve 'safe' GH levels.
    Aylwin S
    Clin Endocrinol (Oxf); 2006 Jul; 65(1):133. PubMed ID: 16817834
    [No Abstract]   [Full Text] [Related]  

  • 27. Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study.
    Ronchi CL; Boschetti M; Degli Uberti EC; Mariotti S; Grottoli S; Loli P; Lombardi G; Tamburrano G; Arvigo M; Angeletti G; Boscani PF; Beck-Peccoz P; Arosio M;
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):512-9. PubMed ID: 17555511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GH secretory dynamics and responsiveness to SMS 201-995 treatment in acromegaly.
    Kim SW; Kim SY; Yang IM; Kim JW; Kim YS; Kim KW; Choi YK
    Korean J Intern Med; 1988 Jul; 3(2):110-6. PubMed ID: 3155299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human pancreatic growth hormone-releasing factor (hpGRF-44) in acromegaly before and after adenomectomy. Modifications induced by somatostatin (GHRIH) infusion.
    Arosio M; Ambrosi B; Guglielmino L; Faglia G
    J Endocrinol Invest; 1985 Oct; 8(5):449-53. PubMed ID: 2867112
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Physiological role of somatostatin-mediated autofeedback regulation for growth hormone: importance of growth hormone in triggering somatostatin release during a trough period of pulsatile growth hormone release in conscious male rats.
    Sato M; Chihara K; Kita T; Kashio Y; Okimura Y; Kitajima N; Fujita T
    Neuroendocrinology; 1989 Aug; 50(2):139-51. PubMed ID: 2571099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interaction between somatostatin and TRH on growth hormone secretion in perifused human growth hormone tumor cells.
    Le Dafniet M; Garnier P; Brandi AM; Bression D; Scherrer H; Racadot J; Peillon F
    Horm Res; 1985; 21(4):235-9. PubMed ID: 2861154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The value of an acute octreotide suppression test in predicting response to long-term somatostatin analogue therapy in patients with acromegaly.
    Bandgar TR; Sarathi V; Shivane V; Bansode N; Menon PS; Shah NS
    J Postgrad Med; 2010; 56(1):7-11. PubMed ID: 20393242
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medical therapy with somatostatin analogues for acromegaly.
    Sassolas G
    Eur J Endocrinol; 1995 Dec; 133(6):675-7. PubMed ID: 8548050
    [No Abstract]   [Full Text] [Related]  

  • 34. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study.
    Colao A; Auriemma RS; Galdiero M; Lombardi G; Pivonello R
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3746-56. PubMed ID: 19622615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
    Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
    J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The growth hormone (GH) response to GH-releasing peptide (His-DTrp-Ala-Trp-DPhe-Lys-NH2), GH-releasing hormone, and thyrotropin-releasing hormone in acromegaly.
    Alster DK; Bowers CY; Jaffe CA; Ho PJ; Barkan AL
    J Clin Endocrinol Metab; 1993 Sep; 77(3):842-5. PubMed ID: 8370708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Somatostatin receptor subtype 2 knockout mice are refractory to growth hormone-negative feedback on arcuate neurons.
    Zheng H; Bailey A; Jiang MH; Honda K; Chen HY; Trumbauer ME; Van der Ploeg LH; Schaeffer JM; Leng G; Smith RG
    Mol Endocrinol; 1997 Oct; 11(11):1709-17. PubMed ID: 9328352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists.
    Howlett TA; Willis D; Walker G; Wass JA; Trainer PJ;
    Clin Endocrinol (Oxf); 2013 Nov; 79(5):689-99. PubMed ID: 23574573
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibitory effects of atropine on growth hormone release in normal subjects and acromegaly.
    Zhang J; Lu JM; Huang ZJ
    Chin Med J (Engl); 1989 Jan; 102(1):45-7. PubMed ID: 2504552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Octreotide suppresses both growth hormone (GH) and GH-releasing hormone (GHRH) in acromegaly due to ectopic GHRH secretion.
    Moller DE; Moses AC; Jones K; Thorner MO; Vance ML
    J Clin Endocrinol Metab; 1989 Feb; 68(2):499-504. PubMed ID: 2493033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.